These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8280948)

  • 21. Absorption of bismuth from two bismuth compounds before and after healing of peptic ulcers.
    Hundal O; Bergseth M; Gharehnia B; Andersen KJ; Berstad A
    Hepatogastroenterology; 1999; 46(29):2882-6. PubMed ID: 10576366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of Helicobacter pylori infection: current status].
    Wagner S; Gebel M; Manns M
    Z Gastroenterol; 1993; 31(7-8):459-63. PubMed ID: 8379235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
    Ghadir MR; Shafaghi A; Iranikhah A; Pakdin A; Joukar F; Mansour-Ghanaei F
    Turk J Gastroenterol; 2011 Feb; 22(1):1-5. PubMed ID: 21480103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of tripotassium dicitrato bismuthate on the rat stomach.
    Waldum HL; Qvigstad G; Mårvik R; Brenna E; Syversen U; Sandvik AK
    Aliment Pharmacol Ther; 1994 Aug; 8(4):425-31. PubMed ID: 7527257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organobismuth compounds: activity against Helicobacter pylori.
    Dahlgren A; Gløgård C; Gammelsaether M; Aasen AJ; Klaveness J; Berdal BP; Bergan T
    Scand J Gastroenterol; 1999 Feb; 34(2):135-7. PubMed ID: 10192189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.
    Yakoob J; Abbas Z; Usman MW; Awan S; Naz S; Jafri F; Hamid S; Jafri W
    Microb Drug Resist; 2014 Aug; 20(4):305-9. PubMed ID: 23844851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
    Hunt RH
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):36S-40S; discussion 40S-43S. PubMed ID: 9127625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
    Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
    Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The actions of bismuth in the treatment of Helicobacter pylori infection.
    Lambert JR; Midolo P
    Aliment Pharmacol Ther; 1997 Apr; 11 Suppl 1():27-33. PubMed ID: 9146788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histochemical tracing of bismuth in Helicobacter pylori after in vitro exposure to bismuth citrate.
    Stoltenberg M; Martiny M; Sørensen K; Rungby J; Krogfelt KA
    Scand J Gastroenterol; 2001 Feb; 36(2):144-8. PubMed ID: 11252405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helicobacter pylori infection. The importance of eradication in patients with gastric disease.
    Bonagura AF; Dabezies MA
    Postgrad Med; 1996 Nov; 100(5):115-6, 119-20, 123-4 passim. PubMed ID: 8917328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea.
    Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):515-9. PubMed ID: 16607147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical indications and efficacy of colloidal bismuth subcitrate.
    Lambert JR
    Scand J Gastroenterol Suppl; 1991; 185():13-21. PubMed ID: 1957121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication.
    Park SM; Park J; Chang SK; Yoo BC; Kim HJ
    Korean J Intern Med; 1996 Jan; 11(1):1-8. PubMed ID: 8882471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of Helicobacter pylori in peptic ulcer disease.
    O'Connor HJ
    Scand J Gastroenterol Suppl; 1994; 201():11-5. PubMed ID: 8047817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.
    Chiba N
    Can J Gastroenterol; 2000 Nov; 14(10):885-9. PubMed ID: 11111112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.
    Walsh JH; Peterson WL
    N Engl J Med; 1995 Oct; 333(15):984-91. PubMed ID: 7666920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current therapy of Helicobacter pylori-induced chronic gastritis and/or peptic ulcer].
    Hentschel E
    Wien Klin Wochenschr; 1994; 106(17):543-6. PubMed ID: 7975668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole.
    Nijevitch AA; Farztdinov KM; Sataev VU; Khasanov RSh ; Katayev VA; Khusnutdinov SM; Akhunov ED; Kazykhanov NS
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1243-50. PubMed ID: 11129216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease.
    Tytgat GN
    Aliment Pharmacol Ther; 1995; 9 Suppl 1():39-42. PubMed ID: 7495941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.